Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuria
- Funding: Study supported by Alexion Pharmaceuticals.
- Conflict of interest: I. W. has received speaker honoraria, as well as an unrestricted research grant, from Alexion Pharmaceuticals; G. M., R. J. K. and A. H. have received honoraria and participated in an Advisory Board for Alexion Pharmaceuticals; P. H. has received research funding and honoraria from and participated in an Advisory Board for Alexion Pharmaceuticals; B. S. is an employee of Alexion Pharmaceuticals; T. L., J.-Y. C., M. T. U., J. A. G. V. and M. A. S. have nothing to disclose.
Anita Hill, Department of Haematology, St James' Institute of Oncology, Level 3 Bexley Wing, Beckett Street, Leeds LS9 7TF, UK. Email: firstname.lastname@example.org
Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, acquired, clonal haemopoietic stem cell disorder that causes chronic intravascular haemolysis, increases the risk of thrombosis and results in significant patient morbidity and mortality. The symptoms of PNH may have a major impact on patient quality of life.
To assess patient fatigue and health-related quality of life in 29 patients with PNH using the Functional Assessment of Chronic Illness Therapy Fatigue subscale version 4 (FACIT-Fatigue) and the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-C30, version 3 (EORTC QLQ-C30).
Following completion of the questionnaires, patients were interviewed to assess the validity, clarity, relevance and comprehensiveness of the assessments.
Overall, patients considered both the FACIT-Fatigue and EORTC QLQ-C30 instruments to be relevant and adequate in assessing the level of PNH-associated fatigue and other quality-of-life measures. The FACIT-Fatigue questionnaire was considered to be clear and to comprehensively cover PNH-related fatigue. The EORTC QLQ-C30 instrument was considered to be easy to understand, but of an overall lower relevance, although some differences between countries were observed. Patients suggested additional questions that could be incorporated into future EORTC QLQ-C30 versions to make it more relevant to PNH.
This study confirms the validity of the FACIT-Fatigue and the EORTC QLQ-C30 questionnaires in this patient population and their routine use should be considered in the management of patients with PNH.